I started trading cheap mining stocks as a Graduate Student in the Neureopsychology Lab of McGill's Allan Memorial Institute before the term "daytrading" was invented. In my spare time, I read everything on investing in the Business School library and I devoured their collection of ...
more I started trading cheap mining stocks as a Graduate Student in the Neureopsychology Lab of McGill's Allan Memorial Institute before the term "daytrading" was invented. In my spare time, I read everything on investing in the Business School library and I devoured their collection of investment-related books and moved to focusing on warrants and trading international E&P companies developing frontier areas. After 25 years as a Professor, I "retired" to do something more exciting:: live off of my investments. During the Tech boom I did a lot of M&A risk arbitrage and option trading. In 2002, I saw an historic opportunity in Petroleum and specialized in Canadian Oil & Gas Trusts. In 2005, I founded the
Trust Intelligence website to provide research and guidance to investors trying to wean them off of relying on sell-side analysts and to teach them to do due diligence from the point of view of an individual investor. While I still watch the oil markets, I am more focused on special situations these days.
less
Latest Comments
Provectus Phase III Melanoma Trial Results Earlier Than Planned?
Even more of a bargain at this point, but it is a waiting game for news. Q1'16 should see some, fundamental advance, although only time will tell market reaction.
Provectus Phase III Melanoma Trial Results Earlier Than Planned?
Lots of things happening for Provectus and in a direction opposite the share price. Their Phase 3 trial has started and will be gaining momentum. See my latest, here: www.trustintelligence.com/.../viewtopic.php
New and probably stunningly good liver cancer data is due out in less than 6 weeks. Hints indicate that this will show efficacy that is way better than anything other drug available or in development. There are over a million people with liver cancer in the US. And with China having 55% of world primary liver cancer, the recently extended MOU with govt.-owned Sinopharm may soon be converted into an official license deal.
They just started talking with Brazil for a South American license and have a number of other deals they are working on. Should be a surprising summer for a stock that does not deserve to be so cheap!
Provectus Phase III Melanoma Trial Results Earlier Than Planned?